Overview

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenstrm Macroglobulinemia

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenstrm Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.

Phase:

PHASE4

Details

Lead Sponsor:

BeiGene

Treatments:

zanubrutinib